{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T19:01:52Z","timestamp":1772910112547,"version":"3.50.1"},"reference-count":101,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmcd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.numecd.2021.09.035","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T18:58:45Z","timestamp":1634151525000},"page":"295-308","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Is Apo-CIII the new cardiovascular target? An analysis of its current clinical and dietetic therapies"],"prefix":"10.1016","volume":"32","author":[{"given":"Lorenzo.G.","family":"de la Parra Soto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet A.","family":"Guti\u00e9rrez-Uribe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashutosh","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurea K.","family":"Ram\u00edrez-Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.numecd.2021.09.035_bib1","series-title":"Cardiovascular diseases (CVDs)","author":"Organization WHO","year":"2017"},{"key":"10.1016\/j.numecd.2021.09.035_bib2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2147\/VHRM.S104369","article-title":"Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease","volume":"12","author":"Toth","year":"2016","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.numecd.2021.09.035_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11883-016-0614-1","article-title":"Why is apolipoprotein CIII emerging as a novel therapeutic target to reduce the burden of cardiovascular disease?","volume":"18","author":"Taskinen","year":"2016","journal-title":"Curr Atherosclerosis Rep"},{"key":"10.1016\/j.numecd.2021.09.035_bib4","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/cvr\/cvv192","article-title":"Aggravated restenosis and atherogenesis in ApoCIII transgenic mice but lack of protection in ApoCIII knockouts: the effect of authentic triglyceride-rich lipoproteins with and without ApoCIII","volume":"107","author":"Li","year":"2015","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.numecd.2021.09.035_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12944-018-0867-5","article-title":"Increased inflammation, endoplasmic reticulum stress and oxidative stress in endothelial and macrophage cells exacerbate atherosclerosis in ApoCIII transgenic mice","volume":"17","author":"Yingchun","year":"2018","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.numecd.2021.09.035_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2020.00088","article-title":"The evolving understanding and approach to residual cardiovascular risk management","volume":"7","author":"Dhindsa","year":"2020","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.numecd.2021.09.035_bib7","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41590-019-0548-1","article-title":"Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activation","volume":"21","author":"Zewinger","year":"2020","journal-title":"Nat Immunol"},{"key":"10.1016\/j.numecd.2021.09.035_bib8","doi-asserted-by":"crossref","DOI":"10.1007\/s11883-019-0791-9","article-title":"Emerging evidence that ApoC-III inhibitors provide novel options to reduce the residual CVD","volume":"21","author":"Taskinen","year":"2019","journal-title":"Curr Atherosclerosis Rep"},{"key":"10.1016\/j.numecd.2021.09.035_bib9","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/clinchem\/hvaa252","article-title":"Residual cardiovascular risk at low LDL: remnants, lipoprotein(a), and inflammation","volume":"67","author":"Hoogeveen","year":"2021","journal-title":"Clin Chem"},{"key":"10.1016\/j.numecd.2021.09.035_bib10","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/MOL.0000000000000672","article-title":"Reducing residual cardiovascular risk with novel therapies","volume":"31","author":"Davidson","year":"2020","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.numecd.2021.09.035_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fendo.2020.00474","article-title":"The roles of ApoC-III on the metabolism of triglyceride-rich lipoproteins in humans","volume":"11","author":"Bor\u00e9n","year":"2020","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.numecd.2021.09.035_bib12","doi-asserted-by":"crossref","DOI":"10.1161\/ATVBAHA.110.220723","article-title":"Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia","author":"Caron","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.numecd.2021.09.035_bib13","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.cmet.2010.09.001","article-title":"Regulation of hepatic ApoC3 expression by PGC-1\u03b2 mediates hypolipidemic effect of nicotinic acid","volume":"12","author":"Hernandez","year":"2010","journal-title":"Cell Metabol"},{"key":"10.1016\/j.numecd.2021.09.035_bib14","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1172\/JCI200419992","article-title":"Foxo1 mediates insulin action on apoC-III and triglyceride metabolism","volume":"114","author":"Altomonte","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.numecd.2021.09.035_bib15","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.bbrc.2017.07.116","article-title":"Key differences between apoC-III regulation and expression in intestine intestine and liver","volume":"491","author":"West","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.numecd.2021.09.035_bib16","doi-asserted-by":"crossref","first-page":"81","DOI":"10.5551\/jat1994.3.81","article-title":"Regulation of triglyceride metabolism by PPARs : fibrates and thiazolidinediones have distinct effects","volume":"3","author":"Auwerx","year":"1996","journal-title":"J Atherosclerosis Thromb"},{"key":"10.1016\/j.numecd.2021.09.035_bib17","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1042\/CS20070308","article-title":"Apolipoprotein C-III: understanding an emerging cardiovascular risk factor","volume":"114","author":"Ooi","year":"2008","journal-title":"Clin Sci"},{"key":"10.1016\/j.numecd.2021.09.035_bib18","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1373\/clinchem.2004.040477","article-title":"Apolipoprotein C-III, n-3 polyunsaturated fatty acids, and \u201cinsulin-resistant\u201d T-455C APOC3 gene polymorphism in heart disease patients: example of gene-diet interaction","volume":"51","author":"Olivieri","year":"2005","journal-title":"Clin Chem"},{"key":"10.1016\/j.numecd.2021.09.035_bib19","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1113\/EP088088","article-title":"MicroRNA-424-5p regulates aortic smooth muscle cell function in atherosclerosis by blocking APOC3-mediated nuclear factor-\u03baB signalling pathway","volume":"105","author":"Li","year":"2020","journal-title":"Exp Physiol"},{"key":"10.1016\/j.numecd.2021.09.035_bib20","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s11033-020-06071-5","article-title":"Apolipoprotein C-III and cardiovascular diseases: when genetics meet molecular pathologies","volume":"48","author":"Dib","year":"2021","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.numecd.2021.09.035_bib21","first-page":"1","article-title":"Small dense low-density lipoprotein cholesterol: a residual risk for rapid progression of non-culprit coronary lesion in patients with acute coronary syndrome","author":"Sekimoto","year":"2021","journal-title":"J Atherosclerosis Thromb"},{"key":"10.1016\/j.numecd.2021.09.035_bib22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.atherosclerosis.2018.11.006","article-title":"Plasma levels of apolipoproteins C-III, A-IV, and E are independently associated with stable atherosclerotic cardiovascular disease","volume":"281","author":"Dittrich","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2021.09.035_bib23","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1172\/JCI86610","article-title":"ApoC-III modulates clearance of triglyceride-rich lipoproteins in mice through low density lipoprotein family receptors","volume":"126","author":"Gordts","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.numecd.2021.09.035_bib24","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/ng.3561","article-title":"Variants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary disease","volume":"48","author":"Helgadottir","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.numecd.2021.09.035_bib25","doi-asserted-by":"crossref","first-page":"33997","DOI":"10.1074\/jbc.M113.495366","article-title":"Apolipoproteins C-I and C-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets","volume":"288","author":"Larsson","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.numecd.2021.09.035_bib26","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.cca.2016.06.016","article-title":"Apoprotein C-III: a review of its clinical implications","volume":"460","author":"Jin","year":"2016","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.numecd.2021.09.035_bib27","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1172\/JCI86610","article-title":"ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors","volume":"126","author":"Gordts","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.numecd.2021.09.035_bib28","doi-asserted-by":"crossref","first-page":"27769","DOI":"10.1074\/jbc.M110.203679","article-title":"Missense mutation in APOC3 within the C-terminal lipid binding domain of human ApoC-III results in impaired assembly and secretion of triacylglycerol-rich very low density lipoproteins: evidence that ApoC-III plays a major role in the formation of lipid p","volume":"286","author":"Qin","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.numecd.2021.09.035_bib29","article-title":"Human apolipoprotein C-III \u2013 a new intrahepatic protein factor promoting assembly and secretion of very low density lipoproteins","author":"Yao","year":"2013","journal-title":"Cardiovasc Hematol Disord Targets"},{"key":"10.1016\/j.numecd.2021.09.035_bib30","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/MOL.0000000000000146","article-title":"The crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia","volume":"26","author":"Sacks","year":"2015","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.numecd.2021.09.035_bib31","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/MED.0000000000000136","article-title":"Apolipoprotein C-III: a potent modulator of hypertriglyceridemia and cardiovascular disease","volume":"22","author":"Kohan","year":"2015","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.numecd.2021.09.035_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12944-020-01293-9","article-title":"Apolipoprotein CIII predicts cardiovascular events in patients with coronary artery disease: a prospective observational study","volume":"19","author":"Katzmann","year":"2020","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.numecd.2021.09.035_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/JAHA.118.010973","article-title":"Not just arterial damage: increased incidence of venous thromboembolic events in cardiovascular patients with elevated plasma levels of apolipoprotein CIII","volume":"8","author":"Olivieri","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.numecd.2021.09.035_bib34","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1161\/STROKEAHA.119.026811","article-title":"Increased incidence of ischemic cerebrovascular events in cardiovascular patients with elevated apolipoprotein CIII","volume":"51","author":"Olivieri","year":"2020","journal-title":"Stroke"},{"key":"10.1016\/j.numecd.2021.09.035_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/JAHA.113.000440","article-title":"Factor II activity is similarly increased in patients with elevated apolipoprotein CIII and in carriers of the factor II 20210A allele","volume":"2","author":"Olivieri","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.numecd.2021.09.035_bib36","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1055\/s-0038-1676817","article-title":"Apolipoprotein C-III strongly correlates with activated factor VII-Anti-Thrombin complex: an additional link between plasma lipids and coagulation","volume":"119","author":"Martinelli","year":"2019","journal-title":"Thromb Haemostasis"},{"key":"10.1016\/j.numecd.2021.09.035_bib37","doi-asserted-by":"crossref","DOI":"10.1194\/jlr.M077925","article-title":"Pleiotropic effects of apolipoprotein C3 on HDL functionality and adipose tissue metabolic activity","author":"Zvintzou","year":"2017","journal-title":"J Lipid Res"},{"key":"10.1016\/j.numecd.2021.09.035_bib38","first-page":"1","article-title":"ApoCIII enrichment in HDL impairs HDL-mediated cholesterol efflux capacity","volume":"7","author":"Luo","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.numecd.2021.09.035_bib39","doi-asserted-by":"crossref","DOI":"10.1021\/bi801249c","article-title":"ABCA1 promotes the de novo biogenesis of apolipoprotein CIII-containing HDL particles in\u00a0vivo and modulates the severity of apolipoprotein CIII-induced hypertriglyceridemia","author":"Kypreos","year":"2008","journal-title":"Biochemistry"},{"key":"10.1016\/j.numecd.2021.09.035_bib40","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1476-511X-13-170","article-title":"Apolipoprotein C3 genetic polymorphisms are associated with lipids and coronary artery disease in a Chinese population","volume":"13","author":"Cui","year":"2014","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.numecd.2021.09.035_bib41","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1307095","article-title":"Loss-of-function mutations in APOC3, triglycerides, and coronary disease","volume":"371","author":"Crosby","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2021.09.035_bib42","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1161\/ATVBAHA.118.311476","article-title":"Effects of APOC3 heterozygous deficiency on plasma lipid and lipoprotein metabolism","volume":"39","author":"Reyes-Soffer","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.numecd.2021.09.035_bib43","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1308027","article-title":"Loss-of-Function mutations in APOC3 and risk of ischemic vascular disease","volume":"371","author":"J\u00f8rgensen","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2021.09.035_bib44","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1161\/ATVBAHA.117.310473","article-title":"APOC3 loss-of-function mutations, remnant cholesterol, low-density lipoprotein cholesterol, and cardiovascular risk: mediation-and meta-analyses of 137 895 individuals","volume":"38","author":"Wulff","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.numecd.2021.09.035_bib45","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1253\/circj.CJ-19-0047","article-title":"Remnant lipoproteins are residual risk factor for future cardiovascular events in patients with stable coronary artery disease and on-statin low-density lipoprotein cholesterol levels <70 mg\/dL","volume":"83","author":"Fujihara","year":"2019","journal-title":"Circ J"},{"key":"10.1016\/j.numecd.2021.09.035_bib46","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s10557-021-07168-0","article-title":"Genetics of triglyceride-rich lipoproteins guide identification of pharmacotherapy for cardiovascular risk reduction","volume":"35","author":"Shaik","year":"2021","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.numecd.2021.09.035_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12944-018-0830-5","article-title":"Association of plasma apolipoprotein CIII, high sensitivity C-reactive protein and tumor necrosis factor-\u03b1 contributes to the clinical features of coronary heart disease in Li and Han ethnic groups in China","volume":"17","author":"Chen","year":"2018","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.numecd.2021.09.035_bib48","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2217\/fca-2020-0216","article-title":"A lipid lover's guide to novel therapeutics for lipid and cardiovascular risk reduction","volume":"17","author":"Hritani","year":"2021","journal-title":"Future Cardiol"},{"key":"10.1016\/j.numecd.2021.09.035_bib49","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1007\/s00125-017-4401-5","article-title":"VLDL and apolipoprotein CIII induce ER stress and inflammation and attenuate insulin signalling via Toll-like receptor 2 in mouse skeletal muscle cells","volume":"60","author":"Botteri","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.numecd.2021.09.035_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pmed.1001971","article-title":"Cardiovascular and renal outcomes of renin\u2013angiotensin system blockade in adult patients with diabetes mellitus: a systematic review with network meta-analyses","volume":"13","author":"Catal\u00e1-L\u00f3pez","year":"2016","journal-title":"PLoS Med"},{"key":"10.1016\/j.numecd.2021.09.035_bib51","doi-asserted-by":"crossref","first-page":"E2611","DOI":"10.1073\/pnas.1423849112","article-title":"Apolipoprotein CIII links islet insulin resistance to \u03b2-cell failure in diabetes","volume":"112","author":"\u00c5vall","year":"2015","journal-title":"Proc Natl Acad Sci Unit States Am"},{"key":"10.1016\/j.numecd.2021.09.035_bib52","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1161\/ATVBAHA.115.305415","article-title":"Plasma ApoC-III levels, triglycerides, and coronary artery calcification in type 2 diabetics","volume":"35","author":"Qamar","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.numecd.2021.09.035_bib53","doi-asserted-by":"crossref","DOI":"10.1002\/hep.24571","article-title":"Apolipoprotein CIII overexpressing mice are predisposed to diet-induced hepatic steatosis and hepatic insulin resistance","author":"Lee","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2021.09.035_bib54","doi-asserted-by":"crossref","DOI":"10.2337\/dc16-0126","article-title":"Antisense-mediated lowering of plasma apolipoprotein C-III by volanesorsen improves dyslipidemia and insulin sensitivity in type 2 diabetes","author":"Digenio","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2021.09.035_bib55","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/aje\/kwx143","article-title":"Apolipoprotein C-III and high-density lipoprotein subspecies defined by apolipoprotein C-III in relation to diabetes risk","volume":"186","author":"Aroner","year":"2017","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.numecd.2021.09.035_bib56","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.metabol.2017.03.016","article-title":"Association of apolipoprotein-CIII (apoC-III), endothelium-dependent vasodilation and peripheral neuropathy in a multi-ethnic population with type 2 diabetes","volume":"72","author":"Pek","year":"2017","journal-title":"Metabolism"},{"key":"10.1016\/j.numecd.2021.09.035_bib57","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.jacl.2016.09.005","article-title":"The effect of omega-3 carboxylic acids on apolipoprotein CIII\u2212containing lipoproteins in severe hypertriglyceridemia","volume":"10","author":"Morton","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.numecd.2021.09.035_bib58","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0021-9150(96)05854-6","article-title":"Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR","volume":"124","author":"Auwerx","year":"1996","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2021.09.035_bib59","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","article-title":"Molecular mechanism of PPAR\u03b1 action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease","volume":"62","author":"Pawlak","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.numecd.2021.09.035_bib60","doi-asserted-by":"crossref","DOI":"10.2337\/dc07-0015","article-title":"Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome","author":"Rosenson","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2021.09.035_bib61","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-021508","article-title":"Effect of fenofibrate on plasma apolipoprotein C-III levels: a systematic review and meta-analysis of randomised placebo-controlled trials","volume":"8","author":"Sahebkar","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.numecd.2021.09.035_bib62","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.5551\/jat.ER39693","article-title":"A novel selective PPAR\u03b1 modulator (SPPARM\u03b1), K-877 (pemafibrate), attenuates postprandial hypertriglyceridemia in mice","volume":"25","author":"Sairyo","year":"2018","journal-title":"J Atherosclerosis Thromb"},{"key":"10.1016\/j.numecd.2021.09.035_bib63","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.atherosclerosis.2016.03.003","article-title":"The novel selective PPAR\u03b1 modulator (SPPARM\u03b1) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis","volume":"249","author":"Hennuyer","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2021.09.035_bib64","doi-asserted-by":"crossref","first-page":"521","DOI":"10.5551\/jat.44412","article-title":"Efficacy and safety of pemafibrate versus fenofibrate in patients with high triglyceride and low HDL cholesterol levels: a multicenter, placebo-controlled, double-blind, randomized trial","volume":"25","author":"Arai","year":"2018","journal-title":"J Atherosclerosis Thromb"},{"key":"10.1016\/j.numecd.2021.09.035_bib65","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20225537","article-title":"Efficacy and safety of pemafibrate, a novel selective peroxisome proliferator-activated receptor \u03b1 modulator (SPPARM\u03b1): pooled analysis of phase 2 and 3 studies in dyslipidemic patients with or without statin combination","volume":"20","author":"Yamashita","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.numecd.2021.09.035_bib66","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ahj.2018.09.011","article-title":"Rationale and design of the pemafibrate to reduce cardiovascular outcomes by reducing triglycerides in patients with diabetes (PROMINENT) study","volume":"206","author":"Pradhan","year":"2018","journal-title":"Am Heart J"},{"key":"10.1016\/j.numecd.2021.09.035_bib67","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.amjcard.2016.02.011","article-title":"A VOYAGER meta-analysis of the impact of statin therapy on low-density lipoprotein cholesterol and triglyceride levels in patients with hypertriglyceridemia","volume":"117","author":"Karlson","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.numecd.2021.09.035_bib68","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.jacl.2018.01.008","article-title":"Effect of statin therapy on plasma apolipoprotein CIII concentrations: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Sahebkar","year":"2018","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.numecd.2021.09.035_bib69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12944-015-0129-8","article-title":"The association of HDL-apoCIII with coronary heart disease and the effect of statin treatment on it","volume":"14","author":"Xiong","year":"2015","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.numecd.2021.09.035_bib70","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.2337\/diacare.27.6.1358","article-title":"Atorvastatin decreases apolipoprotein C-III in apolipoprotein B-containing lipoprotein and HDL in type 2 diabetes: a potential mechanism to lower plasma triglycerides","volume":"27","author":"Dallinga-Thie","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2021.09.035_bib71","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.atherosclerosis.2018.05.014","article-title":"Apolipoprotein CIII and N-terminal prohormone b-type natriuretic peptide as independent predictors for cardiovascular disease in type 2 diabetes","volume":"274","author":"Colombo","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2021.09.035_bib72","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1161\/CIRCRESAHA.111.300367","article-title":"Antisense oligonucleotide inhibition of apolipoprotein CIII reduces plasma triglycerides in rodents, nonhuman primates, and humans","volume":"112","author":"Graham","year":"2013","journal-title":"Circ Res"},{"key":"10.1016\/j.numecd.2021.09.035_bib73","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1194\/jlr.M066399","article-title":"Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results","volume":"57","author":"Yang","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.numecd.2021.09.035_bib74","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.atherosclerosissup.2018.04.074","article-title":"Apolipoprotein C-III inhibition with volanesorsen in patients with hypertriglyceridemia (COMPASS): a randomized, double-blind, placebo-controlled trial","volume":"32","author":"Gouni-Berthold","year":"2018","journal-title":"Atherosclerosis Suppl"},{"key":"10.1016\/j.numecd.2021.09.035_bib75","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.jacc.2016.11.065","article-title":"Very-low-density lipoprotein\u2013associated apolipoproteins predict cardiovascular events and are lowered by inhibition of APOC-III","volume":"69","author":"Pechlaner","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2021.09.035_bib76","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2021.09.035_bib77","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1093\/eurheartj\/ehz209","article-title":"N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels","volume":"40","author":"Alexander","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2021.09.035_bib78","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCRESAHA.111.300367","article-title":"Antisense oligonucleotide inhibition of apolipoprotein CIII reduces plasma triglycerides in rodents, nonhuman primates, and humans","author":"Graham","year":"2013","journal-title":"Circ Res"},{"key":"10.1016\/j.numecd.2021.09.035_bib79","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa1908077","article-title":"Ticagrelor in patients with stable coronary disease and diabetes","volume":"381","author":"Steg","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2021.09.035_bib80","doi-asserted-by":"crossref","DOI":"10.1159\/000176951","article-title":"Effects of severe caloric restriction on the degree of sialylation of apoprotein C-III in obese women","author":"Bosello","year":"1985","journal-title":"Ann Nutr Metab"},{"key":"10.1016\/j.numecd.2021.09.035_bib81","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jacl.2016.12.009","article-title":"Changes in low-density lipoprotein size phenotypes associate with changes in apolipoprotein C-III glycoforms after dietary interventions","volume":"11","author":"Mendoza","year":"2017","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.numecd.2021.09.035_bib82","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/MOL.0000000000000653","article-title":"Dietary fructose and dyslipidemia: new mechanisms involving apoC3","volume":"31","author":"Hieronimus","year":"2020","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.numecd.2021.09.035_bib83","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI81993","article-title":"ChREBP regulates fructose-induced glucose production independently of insulin signaling","volume":"126","author":"Kim","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.numecd.2021.09.035_bib84","doi-asserted-by":"crossref","first-page":"913","DOI":"10.3390\/jcm8070913","article-title":"Effects of fructose or glucose on circulating ApoCIII and triglyceride and cholesterol content of lipoprotein subfractions in humans","volume":"8","author":"Hieronimus","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.numecd.2021.09.035_bib85","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.atherosclerosis.2016.06.048","article-title":"Short-term isocaloric fructose restriction lowers apoC-III levels and yields less atherogenic lipoprotein profiles in children with obesity and metabolic syndrome","volume":"253","author":"Gugliucci","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2021.09.035_bib86","first-page":"524","article-title":"A high-carbohydrate diet enhances the adverse effect of the S2 allele of APOC3 SstI polymorphism on the TG\/HDL-C ratio only in young Chinese females","volume":"44","author":"Song","year":"2011","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.numecd.2021.09.035_bib87","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.plefa.2016.10.001","article-title":"Long-chain polyunsaturated fatty acids regulation of PPARs, signaling: relationship to tissue development and aging","volume":"114","author":"Echeverr\u00eda","year":"2016","journal-title":"Prostagl Leukot Essent Fat Acids"},{"key":"10.1016\/j.numecd.2021.09.035_bib88","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1080\/13543784.2017.1312339","article-title":"PPAR-\u03b1 agonists are still on the rise: an update on clinical and experimental findings","volume":"26","author":"Ferri","year":"2017","journal-title":"Expet Opin Invest Drugs"},{"key":"10.1016\/j.numecd.2021.09.035_bib89","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11010-010-0609-0","article-title":"Effect of dietary saturated fatty acids on HNF-4\u03b1 DNA binding activity and ApoCIII mRNA in sedentary rat liver","volume":"347","author":"Ceccarelli","year":"2011","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.numecd.2021.09.035_bib90","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.jacl.2018.08.003","article-title":"Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: a double-blind, randomized, placebo-controlled study","volume":"12","author":"Oscarsson","year":"2018","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.numecd.2021.09.035_bib91","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jacl.2014.12.001","article-title":"Dose-response effects of marine omega-3 fatty acids on apolipoproteins, apolipoprotein-defined lipoprotein subclasses, and Lp-PLA2 in individuals with moderate hypertriglyceridemia","volume":"9","author":"Skulas-Ray","year":"2015","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.numecd.2021.09.035_bib92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.plefa.2018.01.001","article-title":"Safety and tolerability of prescription omega-3 fatty acids: a systematic review and meta-analysis of randomized controlled trials","volume":"129","author":"Chang","year":"2018","journal-title":"Prostagl Leukot Essent Fat Acids"},{"key":"10.1016\/j.numecd.2021.09.035_bib93","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/ejcn.2012.118","article-title":"Effects of dietary saturated fat on LDL subclasses and apolipoprotein CIII in men","volume":"66","author":"Faghihnia","year":"2012","journal-title":"Eur J Clin Nutr"},{"key":"10.1016\/j.numecd.2021.09.035_bib94","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1093\/jn\/nxaa202","article-title":"The positive association between plasma myristic acid and apocIII concentrations in cardiovascular disease patients is supported by the effects of myristic acid in hepg2 cells","volume":"150","author":"Olivieri","year":"2020","journal-title":"J Nutr"},{"key":"10.1016\/j.numecd.2021.09.035_bib95","first-page":"282","article-title":"Effects of phytosterol ester-enriched vegetable oil on plasma lipoproteins in healthy men","volume":"12","author":"Seki","year":"2003","journal-title":"Asia Pac J Clin Nutr"},{"key":"10.1016\/j.numecd.2021.09.035_bib96","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.3945\/jn.108.103481","article-title":"A plant stanol yogurt drink alone or combined with a low-dose statin lowers serum triacylglycerol and non-HDL cholesterol in metabolic syndrome patients","volume":"139","author":"Plat","year":"2009","journal-title":"J Nutr"},{"key":"10.1016\/j.numecd.2021.09.035_bib97","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.biopha.2017.11.116","article-title":"Lycopene amends LPS induced oxidative stress and hypertriglyceridemia via modulating PCSK-9 expression and Apo-CIII mediated lipoprotein lipase activity","volume":"96","author":"Alvi","year":"2017","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.numecd.2021.09.035_bib98","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.jff.2015.06.047","article-title":"Hepatic genome-wide expression of lipid metabolism in diet-induced obesity rats treated with cocoa polyphenols","volume":"17","author":"Ali","year":"2015","journal-title":"J Funct Foods"},{"key":"10.1016\/j.numecd.2021.09.035_bib99","doi-asserted-by":"crossref","first-page":"111952","DOI":"10.1016\/j.jep.2019.111952","article-title":"Rosa rugosa flavonoids exhibited PPAR\u03b1 agonist-like effects on genetic severe hypertriglyceridemia of mice","volume":"240","author":"Baiyisaiti","year":"2019","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.numecd.2021.09.035_bib100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1096\/fj.04-3095fje","article-title":"Grape seed procyanidins improve atherosclerotic risk index and induce liver CYP7A1 and SHP expression in healthy rats","author":"Del Bas","year":"2005","journal-title":"Faseb J"},{"key":"10.1016\/j.numecd.2021.09.035_bib101","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1111\/dom.13686","article-title":"Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52-week data from the PROVIDE study","volume":"21","author":"Araki","year":"2019","journal-title":"Diabetes Obes Metabol"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475321004956?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475321004956?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:19:12Z","timestamp":1760545152000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475321004956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":101,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0939475321004956"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2021.09.035","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is Apo-CIII the new cardiovascular target? An analysis of its current clinical and dietetic therapies","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2021.09.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}